Pegylated interferon-α-based treatment for chronic hepatitis C in renal transplant recipients: An open pilot study

Transplant International

Volumn 22, Issue 5, 2009, Pages 562-567

  Pageaux, Georges Philippe ^a   Hilleret, Marie Noelle ^b   Garrigues, Valérie ^c   Bismuth, Michael ^a   Audin Mamlouk, Héla ^a   Zarski, Jean Pierre ^b   Mourad, Georges ^c  

^a HÔPITAL SAINT ELOI   (France)

^b HÔPITAL MICHALLON   (France)

^c LAPEYRONIE HOSPITAL   (France)

Author keywords

Hepatitis C; Pegylated interferon; Renal transplantation

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; STEROID; TACROLIMUS;

ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG EFFECT; DRUG RESPONSE; DRUG SAFETY; DRUG USE; GENOTYPE; HEMOLYTIC UREMIC SYNDROME; HEPATITIS C; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MALE; OPEN STUDY; PILOT STUDY; PRIORITY JOURNAL; RENAL GRAFT DYSFUNCTION;

ADULT; AGED; ANTIVIRAL AGENTS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PILOT PROJECTS; POLYETHYLENE GLYCOLS; RIBAVIRIN;

EID: 64249090485     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2008.00831.x     Document Type: Article

References (23)

1. Pereira BJ, Levey AS. Hepatitis C virus infection in dialysis and renal transplantation. Kidney Int 1997 51 : 981.
2. Fabrizi F, Bromberg J, Elli A, Dixit V, Martin P. Review article: hepatitis C virus and calcineurine inhibition after renal transplantation. Aliment Pharmacol Ther 2005 25 : 657.
3. Viral Hepatitis guidelines in hemodialysis and transplantation. Am J Transplant 2004 4 (Suppl. 10 72.
4. Toth CM, Pascual M, Chung RT, et al. Hepatitis C virus-associated fibrosing cholestatic hepatitis after renal transplantation : response to interferon-alpha therapy. Transplantation 1998 66 : 1254.
5. Kamar N, Sandres-Saune K, Selves J, et al. Long-term ribavirin therapy in hepatitis C virus-positive renal transplant patients: effects on renal function and liver histology. Am J Kidney Dis 2003 42 : 184.
6. Fontaine H, Vallet-Pichard A, Equi-Andrade C, et al. Histopathologic efficacy of ribavirin monotherapy in kidney allograft recipients with chronic hepatitis C. Transplantation 2004 78 : 853.
7. Kamar N, Rostaing L, Sandres-Saune K, Ribes D, Durand D, Izopet J. Amantadine therapy in renal transplant patients with hepatitis C virus infection. J clin virol 2004 30 : 110.
8. Fabrizi F, Lunghi G, Dixit V, Martin P. Meta-analysis: anti-viral therapy of hepatitis C virus-related liver disease in renal transplant patients. Aliment Pharmacol Ther 2006 24 : 1413.
9. Thervet E, Pol S, Legendre C, Gagnadoux M, Cavalcanti R, Kreis H. Low-dose recombinant leukocyte interferon-alpha treatment of hepatitis C viral infection in renal transplant recipients. A pilot study. Transplantation 1994 58 : 625.
10. Magnone M, Holley JL, Shapiro R, et al. Interferon-alpha-induced acute renal allograft rejection. Transplantation 1995 59 : 1068.
11. Rostaing L, Izopet J, Baron E, et al. Preliminary results of treatment of chronic hepatitis C with recombinant interferon-alpha in renal transplant patients. Nephrol Dial Transplant 1995 10 (Suppl. 6 93.
12. Tokumoto T, Tanabe K, Ishikawa N, et al. Effect of interferon-alpha treatment in hemodialysis patients and renal transplant recipients with chronic hepatitis C. Transplant Proc 1999 31 : 2887.
13. Baid S, Tolkoff-Rubin N, Saidman S, et al. Acute tumoral rejection in hepatitis C-infected renal transplant recipients receiving antiviral therapy. Am J Transplant 2003 3 : 74.
14. Magee CC, Abraham K, Farrell J, Dorman T, Walshe JJ. Renal thrombotic microangiopathy associated with interferon-alpha treatment of chronic myeloid leukemia. Am J Kidney Dis 2000 36 : E5.
15. Ohashi N, Yonemura K, Sugiura T, et al. Withdrawal of interferon-alpha results in prompt resolution of thrombocytopenia and hemolysis but not renal failure in hemolytic uremic syndrome caused by interferon-alpha. Am J Kidney Dis 2003 41 : E10.
16. Al-Zahrani H, Gupta V, Minden MD, Messner HA, Lipton JH. Vascular events associated with alpha interferon therapy. Leuk Lymphoma 2003 44 : 471.
17. Zaraa I, Maubec E, Valeyrie-Allanore L, et al. Haemolytic uremic syndrome and acute mesenteric ischemia caused by interferon-alpha-2b in the treatment of Kaposi's sarcoma in an AIDS patient. Ann Dermatol Venereol 2007 134 : 65.
18. Singh N, Gayowski T, Marino IR. Hemolytic uremic syndrome in solid-organ transplant recipient. Transpl Int 1996 9 : 68.
19. Thévenot T, Regimbeau C, Ratziu V, Leroy V, Opolon P, Poynard T. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naïve patients: 1999 update. J Viral Hepat 2001 8 : 48.
20. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alpha-2a in patients with chronic hepatitis C. N Engl J Med 2000 343 : 1666.
21. Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon-alpha-2b to interferon-alpha-2b as initial treatment for chronic hepatitis C. Hepatology 2001 34 : 395.
22. Gupta S, Pittenger A, Swan S, et al. Single-dose pharmacokinetics and safety of pegylated interferon-alpha2b in patients with chronic renal dysfunction. J Clin Pharmacol 2002 42 : 1109.
23. Baid-Agrawal S, Pascual M, Moradpour D, Frei U, Tolkoff-Rubin N. Hepatitis C virus infection in haemodialysis and kidney transplant patients. Rev Med Virol 2008 18 : 97.